Key result
Young age linked to ~79% greater progression risk in renal cell carcinoma with venous tumor thrombus.
Why the study?
Does young age affect progression-free survival in patients with renal cell carcinoma and venous tumor thrombus undergoing surgical treatment?
Cohort (n=468)
No
Does young age affect progression-free survival in patients with renal cell carcinoma and venous tumor thrombus undergoing surgical treatment?
Hazard Ratio: 1.79 (95% CI 1.19–2.7)
Young patients with renal cell carcinoma and venous tumor thrombus exhibit distinct clinicopathological characteristics and shorter progression-free survival compared to older patients.
Young RCC-VTT patients warrant age-stratified prognostic evaluation; leaves open whether age independently modifies outcomes beyond metastasis and grade.
Objectives: This study aimed to characterize the clinicopathological features and survival outcomes of young patients with renal cell carcinoma and venous tumor thrombus (RCC-VTT). Materials and Methods: We retrospectively reviewed 468 patients with RCC-VTT who underwent radical nephrectomy and thrombectomy at a high-volume center. Patients were classified as young (≤40 years, n = 43) or older (>40 years, n = 425). Propensity score matching and overlap weighting were used to improve intergroup comparability. Kaplan–Meier analysis and Cox regression were used to evaluate survival outcomes and prognostic associations. Results: Compared with older patients, young patients had larger tumors, more frequent enlarged lymph nodes, more advanced T stages, and greater perioperative transfusion requirements. They also exhibited distinct histological profiles, with higher proportions of papillary RCC and molecularly defined subtypes. Young age was associated with shorter progression-free survival (PFS) in the unadjusted analysis (hazard ratio, 1.79; 95% confidence interval, 1.19–2.70) and remained associated with shorter PFS after accounting for measured clinicopathological characteristics. Across multivariable modeling approaches, young age was consistently retained in the PFS models, together with established prognostic factors, including distant metastasis and nuclear grade. Conclusions: Among patients with RCC-VTT undergoing surgical treatment, young patients exhibited distinct clinicopathological characteristics and shorter PFS. These findings suggest that age-related prognostic differences may not be fully explained by conventional clinicopathological characteristics and warrant further biological investigation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a cohort in Renal cell carcinoma and venous tumor thrombus (RCC-VTT) (n=468). Young age (≤40 years) vs. Older age (>40 years) was evaluated on Progression-free survival (PFS) (HR 1.79, 95% CI 1.19-2.70). Young age (≤40 years) was associated with shorter progression-free survival compared to older age in patients with renal cell carcinoma and venous tumor thrombus (HR 1.79; 95% CI 1.19-2.70).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: